Vážený uživateli, je nám líto, ale Váš prohlížeč nepodporuje plné zobrazení webu. Doporučujeme Vám přejít na jeho aktuálnější verzi (MS Edge) nebo na některý z nejčastějších prohlížečů (Chrome, Firefox, Safari).

AZ entered deal with Harbour Biomed for Claudin18.2 bispecific for up to $350 million

SOTIO Biotech

1/5/2022 | 2 minuty čtení

Vytisknout
Kopírovat odkaz

PARTNERING

Harbour Biomed announced license agreement with AZ for Claudin18.2 targeting bispecific antibody

Harbour BioMed announced a global out-license agreement with AstraZeneca for CLDN18.2xCD3 bispecific antibody HBM7022, a novel bispecific antibody generated from HBM's HCAb Based Immune Cell Engagers (HBICE) Platform. This license agreement and recognition by an industry-leading global biopharmaceutical company marks a major milestone in HBM's business development, validating the potential of the Company's technology platform and innovation capabilities. HBM7022 is a bispecific antibody, currently in pre-clinical stage, that crosslinks tumor cells and T cells by targeting a tumor-associated antigen (Claudin18.2) and CD3, and thus leads to potent T cell activation and tumor elimination.

AstraZeneca will be granted an exclusive global license for research, development, registration, manufacturing, and commercialization of HBM7022 and shall be solely responsible for all costs and activities associated with its further development and commercialization. HBM shall receive an upfront payment of $25 million with the potential for additional payments up to $325 million pending achievement of certain development, regulatory and commercial milestones. HBM is also eligible to receive tiered royalties on net sales.

Pregene entered into innovative partnership with CellPoint to develop anti-BCMA CAR-T

Shenzhen Pregene Biopharma and CellPoint announced an exclusive license agreement for the development and commercialization of PRG-1801, Pregene's single domain antibody-based anti-BCMA CAR-T program, for the treatment of hematological indications in Europe and US. PRG-1801 is a single domain antibody anti-BCMA CAR-T cell therapy in development for the treatment of relapsed/refractory multiple myeloma that has demonstrated strong signs of efficacy and an excellent safety profile in its initial investigator-initiated trial and Phase 1/2 trials.

Pregene will receive over €20 million of upfront and near-term consideration, and is eligible to receive additional development, commercial milestone, and royalty payments. CellPoint will be responsible for the development and commercialization of the anti-BCMA CAR-T therapy in Europe and the US. As part of this partnership, Pregene will also provide translational and lentivirus manufacturing services to be reimbursed by Cellpoint.

Overview of transactions in oncology (values in m$)

Source

Partner

Product

Stage

Rights

Value

UF

MS

Sierra Oncology

GSK

Acquisition of company developing small molecules against JAK-1 momelotinib and two other Phase 1 molecules

Ph 3

NV

1 900

1 900

0

Checkmate Pharma

Regeneron

Acquisition of company developing vidutolimod, a TLR9 agonist encased in virus-like particle for CSCC

Ph 2

NV

250

250

0

Zentalis Pharma

Pfizer

Acquisition of 2% stake in company developing small molecules with lead ZN-c3 targeting WEE1 against sarcoma

Ph 1/2

NV

25

25

0

Werewolf Therapeutics

Jazz Pharma

License to IFNA2B prodrug WTX-613 developed against cancer indications

Precl

WW

1 315

15

1 300

Actinium Pharma

Immedica Biopharma

License to CD-45 antibody radiation conjugate Iomab-B for acute myelogenous leukemia

Ph 3

Europe, M.East, N.Africa

452

35

417

Harbour Biomed

AstraZeneca

License to bispecific antibody targeting CD3 and Claudin18.2 HBM7022 against pancreatic cancer

Precl

WW

350

25

325

Eli Lilly

Telix Pharma

License to olaratumab targeting PDGFRa to be used as radiolabeled compound against soft tissue sarcoma

Res

WW

230

5

225

GenFleet Therapeutics

Sellas Life Sciences

License to small molecule CDK9 inhibitor GFH009 developed against hematolo-gical malignancies

Ph 1

Ex-CN, HK,TW, MC

150

10

140

Shenzhen Pregene Bio

CellPoint

License to BCMA targeting CAR-T therapy PRG-1801 against multiple myeloma

Ph 1/2

US, Europe

NA

22

NA

NASDAQ Initial Public Offerings (IPOs) in oncology

None

Sdílet na sociálních sítích

Sdílet na sociálních sítích

Vytisknout

Kopírovat odkaz